Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Epitalon | FOXO4-DRI | |
|---|---|---|
| Category | Growth Factors | Peptides |
| Standard Dose | — | Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly. |
| Timing | — | No established timing protocol. |
| Cycle Duration | — | Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established. |
| Evidence Level | Emerging | animal_plus_anecdotal |
Synthetic tetrapeptide studied in Russian longevity literature for pineal signaling, circadian regulation, and telomerase-related hypotheses.
FOXO4-DRI is a D-retro-inverso peptide that selectively targets the FOXO4-p53 protein-protein interaction in senescent cells. In senescence, FOXO4 binds p53's disordered transactivation domain (TAD2) in the nucleus, preventing p53 from translocating to mitochondria where it would trigger apoptosis. FOXO4-DRI competitively disrupts this interaction, causing nuclear exclusion of p53 and its redirection to mitochondria, selectively inducing apoptosis in senescent cells while sparing healthy cells. The D-retro-inverso configuration provides protease resistance.
Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly.
No established timing protocol.
Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →